<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05025748</url>
  </required_header>
  <id_info>
    <org_study_id>2021-025</org_study_id>
    <nct_id>NCT05025748</nct_id>
  </id_info>
  <brief_title>Ask Questions (ASQ):Implementation of a Communication Intervention</brief_title>
  <official_title>Ask Questions (ASQ): Implementation of a Communication Intervention to Improve Patient-Oncologist Communication in the Outpatient Medical Oncology Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial implements a communication intervention to improve patient-oncologist&#xD;
      communication in the outpatient medical oncology setting. A communication brochure called the&#xD;
      ASQ brochure may help patients prepare for the doctor visit by thinking through the questions&#xD;
      that patients and patients' family want to ask the doctor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient-centered communication is critical to providing high-quality care. In&#xD;
      patient-provider clinical interactions, providers are responsible for several aspects of&#xD;
      patient-centered communication. However, to reach the goal of providing the best possible&#xD;
      treatments, patients should also actively participate by asking questions and expressing&#xD;
      their concerns. Question prompt lists, simple lists of questions provided to patients before&#xD;
      clinic visits to help them prepare for the appointment, have been tested in several medical&#xD;
      contexts and patient populations, including among an underserved, minority population in&#xD;
      Detroit, and have been shown to contribute to improved outcomes related to better&#xD;
      communication quality. Using a RE-AIM framework, this descriptive, mixed methods, single-arm&#xD;
      intervention study assesses the implementation of an evidence-based communication&#xD;
      intervention (question prompt list), the &quot;ASQ brochure&quot;. The ASQ brochure is designed to&#xD;
      improve patient-oncologist communication and other outcomes by improving patient&#xD;
      self-efficacy for managing patient-physician interactions. Investigators will recruit 225&#xD;
      patients and implement the ASQ brochure at seven Karmanos Cancer Center network sites.&#xD;
      Participants are newly diagnosed patients with (Stages I-IV) cancer for which systemic&#xD;
      therapy is likely a recommended treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self-efficacy in managing patient-physician interactions</measure>
    <time_frame>Baseline (Time 1) to pre-clinic visit (TIme 2) post-clinic visit (TIme 3)</time_frame>
    <description>20 items, 5-point Likert scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in knowledge related to the patient's cancer and treatment</measure>
    <time_frame>Baseline (Time 1) to pre-clinic visit (TIme 2) post-clinic visit (TIme 3)</time_frame>
    <description>6 investigator-developed questions; 5-point Likert scale (strongly disagree - strongly agree)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in trust in physicians</measure>
    <time_frame>Baseline (Time 1) to post-clinic visit (Time 3)</time_frame>
    <description>generally (before) and in a specific physician (after): (5 items20 Likert scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in distress</measure>
    <time_frame>Baseline (Time 1) to pre-clinic visit (TIme 2) post-clinic visit (TIme 3)</time_frame>
    <description>Distress thermometer (one item, Likert scale (no distress - extreme distress)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceptions of the Question Prompt List</measure>
    <time_frame>Post-meeting (Time 3)</time_frame>
    <description>10 items, 5-point Likert scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage III Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <condition>Stage II Colorectal Cancer</condition>
  <condition>Stage III Colorectal Cancer</condition>
  <condition>Stage IV Colorectal Cancer</condition>
  <condition>Stage II Lung Cancer</condition>
  <condition>Stage III Lung Cancer</condition>
  <condition>Stage IV Lung Cancer</condition>
  <condition>Stage II Prostate Cancer</condition>
  <condition>Stage III Prostate Cancer</condition>
  <condition>Stage IV Prostate Cancer</condition>
  <condition>Stage II Ovarian Cancer</condition>
  <condition>Stage III Ovarian Cancer</condition>
  <condition>Stage IV Ovarian Cancer</condition>
  <condition>Stage II Cervical Cancer</condition>
  <condition>Stage III Cervical Cancer</condition>
  <condition>Stage II Bladder Cancer</condition>
  <condition>Stage III Bladder Cancer</condition>
  <condition>Stage IV Bladder Cancer</condition>
  <condition>Stage II Kidney Cancer</condition>
  <condition>Stage III Kidney Cancer</condition>
  <condition>Stage IV Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>Health services research (ASQ brochure)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ASQ brochure and complete questionnaires over 30 minutes at baseline, over 10 minutes pre-clinic visit, and over 30 minutes post-clinic visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Intervention</intervention_name>
    <description>Complete questionnaires</description>
    <arm_group_label>Health services research (ASQ brochure)</arm_group_label>
    <other_name>Questionnaire Administration</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults 18 years of age or older&#xD;
&#xD;
          -  Have a first appointment to see a medical oncologist at a Karmanos Cancer Institute&#xD;
             (KCC) site for medical/systemic treatment for a new, confirmed diagnosis of stages&#xD;
             I-IV cancer&#xD;
&#xD;
          -  Speak and read English well enough to be able to understand consent documents&#xD;
&#xD;
          -  Given the diverse population seen at KCI, we will make attempts to recruit a&#xD;
             representative sample. Our strategy will be simply to ask recruiters to make special&#xD;
             attempts to recruit a representative sample. If that strategy fails after the first 10&#xD;
             patients we will build in requirements that at least 25% of the patients self-identify&#xD;
             as non-White&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Eggly, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Eggly, PhD</last_name>
    <phone>313-576-8260</phone>
    <email>egglys@karmanos.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fatmeh Baidoun, MSW</last_name>
    <email>baidounf@karmanos.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karmanos Cancer Institute at McLaren Bay Region</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Eggly, PhD</last_name>
      <phone>313-576-8260</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute at McLaren Clarkston</name>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <zip>48346</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Eggly, PhD</last_name>
      <phone>313-576-8260</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Eggly, Ph.D.</last_name>
      <phone>313-576-8260</phone>
    </contact>
    <investigator>
      <last_name>Susan Eggly, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lauren Hamel, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seongho Kim, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Voncile Brown-Miller, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute at McLaren Flint</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48532</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Eggly, PhD</last_name>
      <phone>313-576-8260</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute at McLaren Macomb</name>
      <address>
        <city>Mount Clemens</city>
        <state>Michigan</state>
        <zip>48043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Eggly, PhD</last_name>
      <phone>313-576-8260</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute at McLaren Central Michigan</name>
      <address>
        <city>Mount Pleasant</city>
        <state>Michigan</state>
        <zip>48858</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Eggly, PhD</last_name>
      <phone>313-576-8260</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute at McLaren Northern Michigan</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Eggly, PhD</last_name>
      <phone>313-576-8260</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute at McLaren Port Huron</name>
      <address>
        <city>Port Huron</city>
        <state>Michigan</state>
        <zip>48060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Eggly, PhD</last_name>
      <phone>313-576-8260</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Susan Eggly</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

